Indication (Client Specific) Dosage & Frequency Indication GENERIC Treatment of a NAME: variety of cutaneous Butenafine fungal BRANDNAME:

infections, including LOTRIMIN tinea pedis ULTRA, (athletes MENTAX foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor. Route/Dosage /Frequency Topical (Adults and Children> 12 yr): Apply once daily for 2 wk for patients with tinea corporis, tinea cruris, or tinea versicolor. Apply once daily for 4 wk or twice daily for 7 days for patients with tinea pedis.

GN (BN) Classification Stock

Mechanism of Action

Side Effect Adverse Reactions

Nursing Responsibilities includes health teaching and implications (PRE, INTRA, POST) Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication. Consult physician or other health care professional for proper cleansing technique before applying medication. Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by physician or other health care professional. Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes or vaginal area. Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water. Patients with athletes foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change

Affects the synthesis of the fungal cell wall. Therapeutic Effects: Decrease in symptoms of fungal infection.

Local: burning, itching, local hypersensitivity reactions, redness, stinging.

GENERIC NAME: Butoconazole BRAND NAME: Gynezole-1, Mycelex-3

Affects the permeability of the fungal cell wall, allowing leakage of cellular Route/Dosage contents. Not /Frequency active against Vag (Adults bacteria. and Therapeutic Children12 Effects: yr): Vaginal Inhibited growth cream1 and death of applicatorful susceptible (5 g) at Candida, with bedtime for 3 decrease in days accompanying (Mycelex-3)or symptoms of one vulvovaginitis applicatorful (vaginal burning, single dose itching, (Gynezole1). discharge). Indication Treatment of vulvovaginal candidiasis.

GU: itching, pelvic pain, soreness, swelling, vulvovaginal burning.

shoes and socks at least once a day. Advise patient to report increased skin irritation or lack of response to therapy to health care professional. Early relief of symptoms may be seen in 23 days. For tinea cruris, tinea corporis, and tinea versicolor, 2 wk are needed, and for tinea pedis, therapeutic response may take 4 wk. Recurrent fungal infections may be a sign of systemic illness. Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate sensitization and warrant discontinuation of medication. Consult physician or other health care professional for proper cleansing technique before applying medication. Diagnosis should be reconfirmed with smears or cultures before a second course of therapy to rule out other pathogens associated with vulvovaginitis. Recurrent vaginal infections may be a sign of systemic illness. Vag: Applicators are supplied for vaginal administration. Instruct patient to apply

medication as directed for full course of therapy, even if feeling better. Therapy should be continued during menstrual period. Advise patient to avoid using tampons while using this product. Instruct patient on proper use of vaginal applicator. Medication should be inserted high into the vagina at bedtime. Instruct patient to remain recumbent for at least 30 min after insertion. Advise use of sanitary napkins to prevent staining of clothing or bedding. Advise patient to consult health care professional regarding intercourse during therapy. Vaginal medication may cause minor skin irritation in sexual partner. Advise patient to refrain from sexual contact during therapy. Advise patient that this medication may weaken latex or rubber contraceptive products. Another method of contraception should be used during treatment. Advise patient to report to health care professional increased skin irritation or lack of response to therapy. A second course may be necessary if symptoms persist.

GENERIC NAME: Clotrimazole (topical) BRAND NAME: Canesten, Clotrimaderm, Cruex, Lotriderm, Lotrimin AF, Mycelex

Indication Treatment of a variety of cutaneous fungal infections, including cutaneous candidiasis, tinea pedis (athletes foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor. Route/Dosage /Frequency Topical (Adults and Children> 3 yr): Apply cream or solution twice daily for 14 wk.

Affects the permeability of the fungal cell wall, allowing leakage of cellular contents. Therapeutic Effects: Decrease in symptoms of fungal infection.

Local: burning, itching, local hypersensitivity reactions, redness, stinging. Interactions

Advise patient to dispose of applicator after each use. Inform patient that therapeutic response is usually seen after 1 wk. Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication. Consult health care professional for proper cleansing technique before applying medication. Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes. Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water. Patients with athletes foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day. Advise patient to report increased skin irritation or lack of response to therapy to health care professional.

 Inform patient that early relief of symptoms may be seen in 23 days. For Candida, tinea cruris, and tinea corporis, 2 wk are needed, and for tinea pedis, therapeutic response may take 34 wk. Recurrent fungal infections may be a sign of systemic illness.